Martek Biosciences — Investor Presentation (May 2004)
15 slides from Martek Biosciences's investor presentation, May 21, 2004
Slide 1: Martek Revenues ($ millions)
MARTEK REVENUES ($ millions) '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 *Boulder, CO *Winchester, KY *Kingstree, SC * Columbia, MD
Slide 2: History of Martek
History of Martek Spun-off from Martin Marietta - NASA Funded Prgm. Completed IPO Acquired Winchester, KY plant for DHA/ARA DHA/ARA fortified pre-term IF introduced Mgmt. in place with big pharma (Merck) experience DHA/ARA fortified term IF introduced FDA GRAS status U.S. Launched, Purchased OmegaTe
Slide 3: Investment Thesis
Investment Thesis Multiple potential markets: >$250M each Patent protection and regulatory approval Gross profit margin potential > 50% Low cost infrastructure - SG&A and R&D
Slide 4: Benefits of DHA & ARA (Long Chain Polyunsaturated Fatty Acids)
Benefits of DHA & ARA (Long Chain Polyunsaturated Fatty Acids) DHA & ARA Together support infant brain & eye development DHA - Omega 3 Promising research regarding role of DHA in these areas: Reduction of mothers' risk for postpartum depression Lowering of cardiovascular & Syndrome-X risks Lowering
Slide 5: Martek's DHA and its Advantage
Martek's DHA and its Advantage MARTEK'S DHA Derived from algae Fermentation Production EU, FDA, W-W approvals Extensive clinical testing Protected by U.S. and international patents ADVANTAGE Fatty acid match to breast milk All natural / vegetarian Free of pollutants and toxins Infant formula gold st
Slide 6: Progression of Applications
Progression of Applications 12 to 36 months Current 3 to 18 months 48 months.. 36-48 months Infant formula Pregnant & Lactating Toddler Foods First foods for Adults Cardiovascular More Cardiovascular Eye Care More Food Diabetes Dementia Expanded Food Elderly
Slide 7: Cardiovascular Market Situation
Cardiovascular Market Situation Metabolic Syndrome is a growing concern No company has developed a product or a position Recommendations by AHA, IOM, NIH / ISSFAL for Omega-3 consumption have placed physicians on the spot Cautions from AHA, FDA, and EPA concerning contamination in fish and fish oil
Slide 8: Martek's DHA in Metabolic Syndrome (Syndrome-X)
Martek's DHA in Metabolic Syndrome (Syndrome-X) Solution Lowers triglycerides Raises HDL Establishes good heart rhythm Reduces marginal high blood pressure Softens hardened arteries May have favorable effect on insulin resistance
Slide 9: Martek's DHA Solution to Omega-3
Martek's DHA Solution to Omega-3 Free of oceanic contaminants - methyl mercury, dioxins, PCBs No EPA - EPA thins blood, interacts with Aspirin, anti- inflammatories, steroids, and blood thinners Produced under GMP conditions - consistent mg amount from lot to lot Approved by the FDA for infant formu
Slide 10: Manufacturing - Winchester, KY and Kingstree, SC
Manufacturing - Winchester, KY Fully integrated and developed production process > 1M liters of capacity Production process protected by patents & trade secrets Expertise in microalgal fermentation & processing > 180 employees FDA Inspected, GMP, Kosher and Halal certified Manufacturing — Kingstree,
Slide 11: Manufacturing Arachidonic Acid (ARA)
Manufacturing Arachidonic Acid (ARA) Dutch State Mines- $6 - $7 B Multinational fine chemical/fermentation company Produces Martek's ARA under Martek's patents Plants located in Italy and NJ Recent NJ plant incident (negative impact on Q3 sales) New agreement with DSM provides for a cross license of
Slide 12: Manufacturing/Production Expansion Summary
MANUFACTURING/PRODUCTION EXPANSION SUMMARY Independent production at both sites by the end of FY 04 Anticipate capital expenditures of $100M over the next 12-18 months Anticipated annual output from both sites: Current $160M By end of FY'04 $300M By mid FY'05 $500M
Slide 13: Other Martek Products
Other Martek Products Powerful Fluorescence Seed Oil DHA
Slide 14: Recent Developments
Recent Developments Shelf registration statement filed May 21, 2004 Q2 earnings and fiscal 2004 update to be released during the conference call scheduled for the week of June 7th
Slide 15: Slide 15
Martek Biosciences — Investor Presentation (May 2004) on 6ix